World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
62960
World Ranking
7498
National Ranking
107

Overview

Luis Paz-Ares is affiliated with the Complutense University of Madrid in Spain and specializes in medical research with a focus on oncology and pulmonary and respiratory medicine. Their body of work predominantly addresses lung cancer treatments, molecular biology, and cancer research.

The scientist's main fields of study include:

  • Medicine

Their subfields of study cover:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Cancer Research
  • Epidemiology

Main topics in their research involve:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Peptidase Inhibition and Analysis
  • Cancer therapeutics and mechanisms
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies

Frequent co-authors collaborating with Luis Paz-Ares include:

  • Enriqueta Felip
  • Martin Reck
  • Manuel Cobo
  • Óscar Juan
  • Byoung Chul Cho

The researcher frequently publishes in the following venues:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Cancer Research
  • ESMO Open

Notable recent papers by Luis Paz-Ares include:

  • First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407, 2020, Journal of Thoracic Oncology

Best Publications

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    Rafael Rosell;Teresa Moran;Cristina Queralt;Rut Porta

  • Lung cancer: current therapies and new targeted treatments

    Fred R Hirsch;Giorgio V Scagliotti;James L Mulshine;Regina Kwon

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

    GM Mead;SP Stenning;P Cook;SD Fossa

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu

  • First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    Luis Paz-Ares;Tudor-Eliade Ciuleanu;Manuel Cobo;Michael Schenker

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

    Luis Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  • Current Challenges in Cancer Treatment.

    Jon Zugazagoitia;Cristiano Guedes;Santiago Ponce;Irene Ferrer

  • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

    Robert Pirker;Jose R. Pereira;Joachim Von Pawel;Maciej Krzakowski

  • PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

    Luis G. Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

    Joaquim Bellmunt;Hans von der Maase;Graham M. Mead;Iwona Skoneczna

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

    Ricardo Hitt;Antonio López-Pousa;Javier Martínez-Trufero;Vicente Escrig

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

Frequent Co-Authors

David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Amancio Carnero
Amancio Carnero Spanish National Research Council
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Tony Mok
Tony Mok Chinese University of Hong Kong
David Planchard
David Planchard Institut Gustave Roussy
Michael Boyer
Michael Boyer University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a future in medicine but want to explore alternative or complementary pathways, there are several flexible options available online. Programs such as the easiest rn program to get into offer accessible entry points into nursing, ideal for those looking for an efficient route into patient care positions.

For those interested in administrative roles, medical billing and coding schools online provide the skills necessary for vital behind-the-scenes work in healthcare. These programs can be completed remotely and often offer financial aid.

If admissions testing is a concern, you may want to look into a nursing school that does not require teas test, making it easier for students to start their educational journey without additional standardized exams.

For those seeking leadership roles, accelerated healthcare programs can fast-track your preparation for management positions. These online programs are designed for fast completion while maintaining industry standards. Exploring these pathways can expand your options and help you find the best fit for your healthcare career goals.

Best Scientists Citing Luis Paz-Ares

Trending Scientists

Recently Published Articles